Rhumbline Advisers Invests $458,000 in Septerna, Inc. (NASDAQ:SEPN)

Rhumbline Advisers bought a new position in shares of Septerna, Inc. (NASDAQ:SEPN) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 19,995 shares of the company’s stock, valued at approximately $458,000.

Separately, SG Americas Securities LLC purchased a new stake in shares of Septerna during the fourth quarter worth about $185,000.

Insider Activity

In related news, CFO Gil M. Labrucherie bought 5,000 shares of the business’s stock in a transaction on Friday, February 21st. The stock was acquired at an average price of $5.85 per share, with a total value of $29,250.00. Following the transaction, the chief financial officer now owns 30,000 shares in the company, valued at approximately $175,500. This trade represents a 20.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Alan Ezekowitz bought 7,491 shares of the business’s stock in a transaction on Tuesday, March 4th. The stock was bought at an average cost of $6.35 per share, with a total value of $47,567.85. Following the transaction, the director now owns 24,911 shares in the company, valued at $158,184.85. This trade represents a 43.00 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 74,346 shares of company stock worth $439,670.

Septerna Stock Up 1.1 %

SEPN stock opened at $6.43 on Friday. The firm’s 50 day simple moving average is $14.10. Septerna, Inc. has a 52-week low of $4.17 and a 52-week high of $28.99.

Analysts Set New Price Targets

SEPN has been the subject of a number of analyst reports. JPMorgan Chase & Co. initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price for the company. Wells Fargo & Company lowered shares of Septerna from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $43.00 to $14.00 in a report on Tuesday, February 18th. TD Cowen began coverage on shares of Septerna in a report on Tuesday, November 19th. They issued a “buy” rating for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $50.00 target price on shares of Septerna in a report on Tuesday, February 11th.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.